Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIORA THERAPEUTICS, INC.BIOR · Entity 85047 | Director | June 05, 2024 | June 06, 2024 |
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Chief Financial Officer | March 05, 2026 | March 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIORA THERAPEUTICS, INC.
Report date June 05, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,916 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 31,916 F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2034-06-05 | Direct | 12,500 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500 F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
F2: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer.
Lineage Cell Therapeutics, Inc.
Report date March 05, 2026 · Filed March 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2036-03-05 | Direct | 1,050,000 |
Reported balance
After 2026-03-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-05 · Grant · Acquired 1,050,000 · Balance 1,050,000 F1: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 7, 2026 00:50 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,050,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001193125-26-097184 · ownership.xml · derivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,000 Underlying: Common Shares · 1,050,000 shares Expires 2036-03-05 F1 · derivative.exercise_date: One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:30 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0000950170-25-038116 · ownership.xml · derivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Shares · 750,000 shares Expires 2035-03-10 F1 · derivative.exercise_date: One quarter of the options shall vest on March 10, 2026, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| November 26, 2024 Filed Nov 26, 2024 21:58 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 15,000 | $0.59 | $8,850.00 |
DisclosureSEC source: 0000950170-24-131098 · ownership.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5925 to $0.5929, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 1. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 22:24 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | PurchaseCommon Shares | 10,500 | $0.89 | $9,345.00 |
DisclosureSEC source: 0000950170-24-098731 · ownership.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 16:33 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000950170-24-069928 · ownership.xml · derivative · entry 2 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-05 F2 · derivative.exercise_date: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 16:33 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069928 · ownership.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,916 F1 · shares: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:05 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001493152-24-009379 · ownership.xml · derivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Shares · 650,000 shares Expires 2034-03-07 F1 · derivative.exercise_date: One quarter of the options shall vest on March 7, 2025, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0000950170-23-028594 · ownership.xml · derivative · entry 2 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: This option represents the right to purchase 12,500 shares of the Issuer's common stock, and vests in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-028594 · ownership.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,416 F1 · shares: Represents 12,500 restricted stock units, which vest in full on the earlier of (1) the first anniversary of the grant date or (2) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 09, 2023 Filed Mar 11, 2023 00:02 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001493152-23-007304 · ownership.xml · derivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Disposition to issuerSeries X Preferred Stock | 19 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000957 · doc4.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. F2 · price: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. Read SEC document |
| November 14, 2022 Filed Nov 16, 2022 21:17 UTC | Lineage Cell Therapeutics, Inc. LCTX · Entity 6045 | GrantEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-22-032631 · ownership.xml · derivative · entry 1 Howe Jill Ann · CIK 0001892397 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Shares · 1,000,000 shares Expires 2032-11-14 F1 · derivative.exercise_date: This option will vest as to one quarter of the shares subject to the option on November 14, 2023, and the balance will vest in 36 successive substantially equal installments thereafter, subject to the reporting person's continuous employment. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:31 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 148,810 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-22-023096 · doc4.xml · derivative · entry 2 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,810 Underlying: Common Stock · 148,810 shares Expires 2032-06-15 F2 · deemedExecutionDate: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:31 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 96,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023096 · doc4.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,908 F1 · shares: Represents 96,154 restricted stock units, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:35 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 82,879 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0000899243-21-043301 · doc4.xml · derivative · entry 2 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,879 Underlying: Common Stock · 82,879 shares Expires 2031-11-03 F2 · deemedExecutionDate: This option represents the right to purchase 82,879 shares of the Issuer's common stock, which vest in equal installments on the first, second, third and fourth anniversaries of November 3, 2021, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 82,879 shares of the Issuer's common stock, which vest in equal installments on the first, second, third and fourth anniversaries of November 3, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:35 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantCommon Stock | 76,754 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-043301 · doc4.xml · nonDerivative · entry 1 Howe Jill Ann · CIK 0001892397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,754 F1 · shares: Represents 76,754 restricted stock units, which vest in equal installments on the first, second, third and fourth anniversaries of November 3, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.